Last update 11 Jul 2024

Adalimumab biosimilar(Celltrion)

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
Adalimumab biosimilar, ADALIMUMAB-AATY, Yuflyma
+ [2]
Target
Mechanism
TNF-α inhibitors(Tumor necrosis factor α inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
Regulation-
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
--

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Polyarticular Juvenile Idiopathic Arthritis
AU
25 Mar 2022
Ankylosing Spondylitis
EU
11 Feb 2021
Ankylosing Spondylitis
IS
11 Feb 2021
Ankylosing Spondylitis
LI
11 Feb 2021
Ankylosing Spondylitis
NO
11 Feb 2021
Arthritis, Psoriatic
EU
11 Feb 2021
Arthritis, Psoriatic
IS
11 Feb 2021
Arthritis, Psoriatic
LI
11 Feb 2021
Arthritis, Psoriatic
NO
11 Feb 2021
Axial Spondyloarthritis
EU
11 Feb 2021
Axial Spondyloarthritis
IS
11 Feb 2021
Axial Spondyloarthritis
LI
11 Feb 2021
Axial Spondyloarthritis
NO
11 Feb 2021
Colitis, Ulcerative
EU
11 Feb 2021
Colitis, Ulcerative
IS
11 Feb 2021
Colitis, Ulcerative
LI
11 Feb 2021
Colitis, Ulcerative
NO
11 Feb 2021
Crohn Disease
EU
11 Feb 2021
Crohn Disease
IS
11 Feb 2021
Crohn Disease
LI
11 Feb 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
648
jtkgbsvcup(snvgszvver) = ikaoaooxse ievvagjjjp (bxpqszrgml )
Positive
05 Feb 2021
jtkgbsvcup(snvgszvver) = znhwqwxqvb ievvagjjjp (bxpqszrgml )
Phase 1
-
312
(CT-P17)
fvcgrkrjmi(iwaekiflvx) = ilcdvavnes ldmcikawad (aqsgpssodw, tzpsyiupzk - bvhaegivel)
-
11 Dec 2020
(US-licensed Humira)
fvcgrkrjmi(iwaekiflvx) = vapoeptbcu ldmcikawad (aqsgpssodw, xfknuxuffw - bjubdmpstr)
Phase 1
-
180
(Auto Injector)
axvnbllfzc(xvvvqjdapq) = wnxezzdkhu goemwbrgfk (uksxaheztf, bswxbrjoij - iexnhgtbtc)
-
07 Dec 2020
(Pre-filled Syringe)
axvnbllfzc(xvvvqjdapq) = gitowlzrlj goemwbrgfk (uksxaheztf, sjpvnnmhqo - dzvvisgpqa)
Not Applicable
-
-
pcqxcgxefc(jbkbmpxpmn) = djhikpdknt jfacdfiyvl (lrxzkaybdz )
-
10 Nov 2019
EU-reference adalimumab 40 mg
pcqxcgxefc(jbkbmpxpmn) = xkzbkguxuh jfacdfiyvl (lrxzkaybdz )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free